@Article{biocell.2022.020407, AUTHOR = {MARLA DE CERQUEIRA ALVES, MONISE OLIVEIRA SANTOS, NASSIB BEZERRA BUENO, ORLANDO ROBERTO PIMENTEL DE ARAÚJO, MARÍLIA OLIVEIRA FONSECA GOULART, FABIANA ANDRÉA MOURA}, TITLE = {Efficacy of oral consumption of curcumin/ for symptom improvement in inflammatory bowel disease: A systematic review of animal models and a meta-analysis of randomized clinical trials}, JOURNAL = {BIOCELL}, VOLUME = {46}, YEAR = {2022}, NUMBER = {9}, PAGES = {2015--2047}, URL = {http://www.techscience.com/biocell/v46n9/47749}, ISSN = {1667-5746}, ABSTRACT = {

The roots of the vegetal Curcuma due to its high content of polyphenols, has been used successfully in several clinical situations. This review assessed the effect of curcumin/Curcuma longa on symptoms and metabolic changes in inflammatory bowel disease (IBD). A systematic review of animal models and randomized clinical trials (RCTs) was conducted by searching the following electronic databases: PubMed, CENTRAL, LILACS, Science Direct, and ClinicalTrials.gov. From 997 found records, 62 were included. More than 90% of the animal studies reported an improvement in macroscopic, histologic and/or functional activity; 80% identified decreased oxidative and/or inflammatory biomarkers in animals treated with curcumin. Among the RCTs, intention-to-treat analysis showed that oral curcumin was effective in inducing clinical remission (n = 281, RR: 3.15 CI 95% [1.22–8.10] p = 0.0017; i² = 72.2%, p = 0.006) and clinical response (n = 259, RR: 1.60 CI 95% [1.09–2.35] p = 0.0017; i² = 59.7%, p = 0.042) but not endoscopic remission (n = 161, RR: 2.91 CI 95% [0.58–14.58] p = 0.195; i² = 72.7%, p = 0.026). These results confirm that oral supplementation with curcumin/Curcuma longa has beneficial actions in animal colitis and, when associated with drug therapy, is effective in the treatment of patients with IBD.

}, DOI = {10.32604/biocell.2022.020407} }